Myocardial Ischemia - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 64

Myocardial Ischemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, H1 2012', provides an overview of the Myocardial Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Ischemia. 'Myocardial Ischemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myocardial Ischemia.
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myocardial Ischemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Myocardial Ischemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Myocardial Ischemia Therapeutic Products under Development, Key Players in Myocardial Ischemia Therapeutics, Myocardial Ischemia Pipeline Overview, Myocardial Ischemia Pipeline, Myocardial Ischemia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia Overview
Therapeutics Development
An Overview of Pipeline Products for Myocardial Ischemia
Myocardial Ischemia Therapeutics under Development by Companies
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Myocardial Ischemia Therapeutics – Products under Development by Companies
Myocardial Ischemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Myocardial Ischemia Therapeutics Development
Cardium Therapeutics, Inc.
Cook Medical Incorporated
Advanced Cell Technology, Inc.
Cytori Therapeutics, Inc.
CardioVascular BioTherapeutics, Inc.
Unigene Laboratories, Inc.
Viromed Co., Ltd.
Baxter Healthcare Corporation
Eribis Pharmaceuticals AB
Biopeutics co., Ltd.
Myocardial Ischemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Generx - Drug Profile
Annexin Analogs - Drug Profile
VM202 - Drug Profile
Papeilin - Drug Profile
Eprex - Drug Profile
FGF-1141 - Drug Profile
Evasin-3 - Drug Profile
Adenosine - Drug Profile
Ranexa - Drug Profile
EP 94 - Drug Profile
Adipose Tissue-Derived Stem And Regenerative Cells - Drug Profile
Autologous Muscle Derived Cells Transplantation - Drug Profile
Hemangioblast Cell Program - Drug Profile
Adult Autologous CD34+ Stem Cells - Drug Profile
MANF - Drug Profile
Autologous Bone-Marrow Mononuclear Cells - Drug Profile
Myocardial Ischemia Therapeutics – Drug Profile Updates
Myocardial Ischemia Therapeutics - Dormant Products
Myocardial Ischemia – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Myocardial Ischemia, H1 2012
Products under Development for Myocardial Ischemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Cardium Therapeutics, Inc., H1 2012
Cook Medical Incorporated, H1 2012
Advanced Cell Technology, Inc., H1 2012
Cytori Therapeutics, Inc., H1 2012
CardioVascular BioTherapeutics, Inc., H1 2012
Unigene Laboratories, Inc., H1 2012
Viromed Co., Ltd., H1 2012
Baxter Healthcare Corporation, H1 2012
Eribis Pharmaceuticals AB, H1 2012
Biopeutics co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Myocardial Ischemia Therapeutics – Drug Profile Updates
Myocardial Ischemia Therapeutics – Dormant Products
Myocardial Ischemia Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Myocardial Ischemia, H1 2012
Products under Development for Myocardial Ischemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Brain Ischemia - Pipeline Review, H1 2012
• Alzheimer's Disease – Pipeline Review, H1 2013
• Eczema - Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Obesity - Pipeline Review, H1 2013
• Cystic Fibrosis - Pipeline Review, H1 2013
• Thrombocytopenia - Pipeline Review, H1 2013
• Allergic Rhinitis - Pipeline Review, H1 2013
• Male Sexual Dysfunction - Pipeline Review, H1 2013